

# TEAS for Sedation During ERCP: A Multicenter Trial

NCT07440342

---

Status	RECRUITING
Phase	Not Applicable
Sponsor	Beijing 302 Hospital
Enrollment	130 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- Patients aged 18-80 years scheduled for elective diagnostic or therapeutic endoscopic retrograde cholangiopancreatography (ERCP) for pancreaticobiliary indications.
- American Society of Anesthesiologists (ASA) physical status classification I, II, or III.
- Body mass index (BMI) between 18 and 30 kg/m<sup>2</sup>.
- Willing and able to provide written informed consent.

### Exclusion (19)

- Known allergy or contraindication to meperidine, diazepam, or any other medication used in the protocol.
- Chronic use of benzodiazepines or opioids (regular use more than three times per week in the preceding three months).
- Severe cardiopulmonary, hepatic, or renal dysfunction (e.g., New York Heart Association class III or IV heart failure, uncontrolled chronic obstructive pulmonary disease, estimated glomerular filtration rate  $\leq 30$  mL/min/1.73m<sup>2</sup>, active liver disease).
- Anticipated difficult airway (Mallampati score IV, mouth opening  $\leq 3$  cm, thyromental distance  $\leq 6$  cm).
- Untreated or severe obstructive sleep apnea requiring continuous positive airway pressure therapy.

... and 14 more (see full listing online)

## Locations (1 total)

---

The Fifth Medical Center of PLA General Hospital, Beijing, Beijing Municipality, China